SCHEDULE: Euler Fund Reports 6.71% Stake in Lyell Immunopharma

Euler Fund, L.P., along with its general partner Euler Managers Limited and indirect owner Antonis Indianos, has disclosed beneficial ownership of 1,426,528 shares, representing 6.71% of Lyell Immunopharma, Inc.'s common stock.

Summary

• Euler Fund, L.P. (PN) and Euler Managers Limited (CO) have reported beneficial ownership of 1,426,528 shares of Lyell Immunopharma, Inc. common stock.
• This holding represents 6.71% of the total outstanding Class A common stock.
• The percentage is based on 21,243,954 shares of Class A common stock outstanding as of December 18, 2025, according to Lyell Immunopharma's Form 424B5 filing.
• Antonis Indianos (IN), a Cypriot individual, is the indirect owner of Euler Managers Limited and may be deemed to beneficially own these shares.
• Euler Managers Limited is the general partner of Euler Fund, L.P. and may be deemed to beneficially own the shares held by the fund.
• The filing is made under Schedule 13G, indicating the reporting persons are not attempting to influence or change control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, representing a standard disclosure of passive investment rather than a significant strategic development or financial performance update.

Positives

• Significant stake reported by Euler Fund, indicating investor confidence or strategic interest in Lyell Immunopharma.
• The filing is made under Rule 13d-1(b), suggesting the ownership is passive and not for the purpose of influencing control.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures inherent in a Schedule 13G filing.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Lyell Immunopharma. It is a disclosure of beneficial ownership by an investment entity.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Euler Fund's passive investment in Lyell Immunopharma, a biotechnology company, and does not suggest any immediate intent to influence corporate control.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception.
• Management: The passive nature of the filing suggests no immediate pressure on management from this specific reporting entity.

Next Steps

• The reporting persons will continue to monitor their investment in Lyell Immunopharma, Inc.

Key Dates

Keywords

Lyell Immunopharma, Schedule 13G, Euler Fund, Euler Managers Limited, Antonis Indianos, Beneficial Ownership, Common Stock, SEC Filing, Cayman Islands, Cyprus